Chandima Bandara is the CEO of Precision Quantomics, where he leads the company’s mission to revolutionize drug development through high-precision proteomics. With over 20 years of experience spanning biotechnology, business, contract research, and large-scale operations, Chandima brings a rare blend of scientific insight and operational excellence to the biotech industry.
Prior to joining Precision Quantomics, Chandima held a diverse range of roles across the life sciences and technology sectors. He began his career as an R&D scientist, then went on to lead business development and scaled growth at a leading contract research organization (CRO). He later managed world-class logistics and fulfillment operations at Amazon. Over the past six years, he has focused on bringing scientific innovations to market through life sciences startups.
At Precision Quantomics, Chandima is spearheading efforts to develop a comprehensive
proteomics database, a robust LC-MS kit portfolio, and a testing-as-a-service platform—all designed to accelerate pharmaceutical R&D and reduce development costs. Chandima serves on the Board of Trustees for the Health Sciences & Services Authority (HSSA) of Spokane County and has held national board roles with organizations such as the Animal Health Institute (AHI). He is also an active contributor to national initiatives advancing New Approach Methodologies (NAMs) and modernizing regulatory science.
Christy has been a research scientist and laboratory manager for over 20 years,
receiving a M.S. from Purdue University in Molecular Biology and a B.S. from
Oregon State University in Biochemistry and Biophysics. She is a well-organized
manager of people and data, an advocate of critical thinking, and is well-versed in the
generation and validation of data in drug metabolizing model systems. She has
experience establishing and supporting a wide range of academic research programs, and has spent time in pharmaceutical contract manufacturing. Her experience in genetics and molecular biology extends over 25 years; however, during the past 8 years she has been focused on developing in vitro models to better understand variation in human drug metabolism. As shown by her many publications in this field, she has practical expertise in cloning, expressing, and purifying recombinant human drug metabolizing enzymes from both the cytosol and microsomes, as well as an in-depth understanding of enzyme kinetics and drug-drug interactions, preclinical drug metabolism, drug transport, pharmacokinetics, and descriptive statistics. She has been working with Precision Quantomics Inc (PQ) for the past 2 ½ years and was instrumental in acquiring an STTR grant for the development of a database and in vitro reagents focused on addressing health disparities through quantitative systems modeling. She currently serves as the Director of Research and Development, nurturing the small but growing list of academic and industry clients utilizing PQ’s consulting services and contract proteomics services for hire. In addition, she was instrumental in developing and launching PQ’s first product line, an LC/MS-based kit designed for the in-house quantification of a panel of drug-metabolizing enzymes. As the company continues to grow, she is excited to lead future research and commercialization efforts.
receiving a M.S. from Purdue University in Molecular Biology and a B.S. from
Oregon State University in Biochemistry and Biophysics. She is a well-organized
manager of people and data, an advocate of critical thinking, and is well-versed in the
generation and validation of data in drug metabolizing model systems. She has
experience establishing and supporting a wide range of academic research programs, and has spent time in pharmaceutical contract manufacturing. Her experience in genetics and molecular biology extends over 25 years; however, during the past 8 years she has been focused on developing in vitro models to better understand variation in human drug metabolism. As shown by her many publications in this field, she has practical expertise in cloning, expressing, and purifying recombinant human drug metabolizing enzymes from both the cytosol and microsomes, as well as an in-depth understanding of enzyme kinetics and drug-drug interactions, preclinical drug metabolism, drug transport, pharmacokinetics, and descriptive statistics. She has been working with Precision Quantomics Inc (PQ) for the past 2 ½ years and was instrumental in acquiring an STTR grant for the development of a database and in vitro reagents focused on addressing health disparities through quantitative systems modeling. She currently serves as the Director of Research and Development, nurturing the small but growing list of academic and industry clients utilizing PQ’s consulting services and contract proteomics services for hire. In addition, she was instrumental in developing and launching PQ’s first product line, an LC/MS-based kit designed for the in-house quantification of a panel of drug-metabolizing enzymes. As the company continues to grow, she is excited to lead future research and commercialization efforts.
